APA (7th ed.) Citation

Roberts, A. W., Seymour, J. F., Brown, J. R., Wierda, W. G., Kipps, T. J., Khaw, S. L., . . . Humerickhouse, R. (2012). Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease. Journal of clinical oncology, 30(5), 488-496. https://doi.org/10.1200/JCO.2011.34.7898

Chicago Style (17th ed.) Citation

Roberts, Andrew W., et al. "Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease." Journal of Clinical Oncology 30, no. 5 (2012): 488-496. https://doi.org/10.1200/JCO.2011.34.7898.

MLA (9th ed.) Citation

Roberts, Andrew W., et al. "Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease." Journal of Clinical Oncology, vol. 30, no. 5, 2012, pp. 488-496, https://doi.org/10.1200/JCO.2011.34.7898.